Acquisition by Phillip Lee of 410000 shares of Vaxart at 0.78 subject to Rule 16b-3
VXRT Stock | USD 0.60 0.01 1.64% |
Slightly above 61% of Vaxart's investor base is looking to short. The analysis of the overall investor sentiment regarding Vaxart Inc suggests that many traders are alarmed. Vaxart's investing sentiment can be driven by a variety of factors including economic data, Vaxart's earnings reports, geopolitical events, and overall market trends.
Vaxart |
Filed transaction by Vaxart Inc Officer Chief Financial Officer. Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
Cash Flow Correlation
Vaxart's cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Vaxart's relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
Vaxart Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Vaxart can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Vaxart Fundamental Analysis
We analyze Vaxart's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vaxart using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vaxart based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Valuation
Current Valuation Comparative Analysis
Vaxart is currently under evaluation in current valuation category among its peers. Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Vaxart Inc Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Vaxart stock to make a market-neutral strategy. Peer analysis of Vaxart could also be used in its relative valuation, which is a method of valuing Vaxart by comparing valuation metrics with similar companies.
Peers
Vaxart Related Equities
INZY | Inozyme Pharma | 0.68 | ||||
PBYI | Puma Biotechnology | 0.68 | ||||
SRPT | Sarepta Therapeutics | 0.73 | ||||
PTGX | Protagonist Therapeutics | 1.51 | ||||
DAWN | Day One | 2.66 | ||||
SNDX | Syndax Pharmaceuticals | 5.34 | ||||
IOVA | Iovance Biotherapeutics | 7.23 | ||||
ZNTL | Zentalis Pharmaceuticals | 10.57 | ||||
MRSN | Mersana Therapeutics | 14.18 |
Additional Tools for Vaxart Stock Analysis
When running Vaxart's price analysis, check to measure Vaxart's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxart is operating at the current time. Most of Vaxart's value examination focuses on studying past and present price action to predict the probability of Vaxart's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxart's price. Additionally, you may evaluate how the addition of Vaxart to your portfolios can decrease your overall portfolio volatility.